HYLORIS PHARMACEUTIC

HYL
Real-time Quote. Real-time  - 05/26 11:35:07 am
14.94EUR -0.27%

Hyloris Pharmaceuticals SA Announces FDA Acceptance of New Drug Application for Maxigesic IV in Post-Operative Pain

11/01/2021 | 01:00am
Hyloris Pharmaceuticals SA committed to addressing unmet medical needs through reinventing existing medications, announced that the U.S. Food and Drug Administration has accepted the New Drug Application for Maxigesic IV, a novel, unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion, for the treatment of post-operative pain. In addition, the company informs that the US Patent and Trademark Office has issued a Notice of Allowance and granted the process and formulation patents of Maxigesic IV in the U.S. The patents are expected to be issued early 2022 after completion of the final administrative requirements. The FDA is expected to confirm the Prescription Drug User Fee Act action date for the filing in due course. The PDUFA date ? the date at which the FDA must respond to the application ? will be notified later this year and is estimated to be between August and September 2022. The NDA submission is based on positive data from two Phase 3 studies of Maxigesic IV: i) a randomised, double-blind, placebo-controlled efficacy trial in 276 patients following bunionectomy surgery; and ii) an open-label, multi-centre, single arm, multiple dose safety study in 232 patients undergoing general, orthopaedic, or plastic surgery. As previously reported, treatment with Maxigesic IV was well-tolerated, had a faster onset of action and offered higher pain relief compared to ibuprofen IV or paracetamol IV alone in the same doses. Moreover, the superior analgesic effect of Maxigesic IV was supported by a range of secondary endpoints, including reduced opioid usage rates compared to the paracetamol IV, ibuprofen IV and placebo treatment groups (P<0.005). The open-label Phase 3 safety study demonstrated that Maxigesic IV, administered 6-hourly as a 15-minute infusion over an exposure period of 48 hours to 5 days, was safe and well-tolerated, and was perceived positively by study participants, supporting a favourable risk benefit profile. Maxigesic IV has been developed under the collaboration agreement signed in 2012 between Hyloris and AFT Pharmaceuticals. The product is currently licensed in over 100 countries across the globe, has been registered in 28 countries and is now launched in 5 countries. Maxigesic IV is protected by several granted patents and pending patent applications.
© S&P Capital IQ 2022
Copier lien
All news about HYLORIS PHARMACEUTICALS SA
04/01
03/31
03/31
03/16
03/16